Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder involving multiple
organs and having diverse clinical manifestations. Among the rheumatic diseases, it has …

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that affects
approximately 250,000 Americans, with a female-to-male ratio of 10: 1. 1 SLE occurs …

ABSTRACT Introduction: Systemic Lupus Erythematosus (SLE) is a chronic B cell-mediated
autoimmune disease which can potentially involve several organs and systems. The …

Systemic lupus erythematosus (SLE) is one of the most challenging autoimmune disorders
with a complex pathophysiology and diverse clinical presentation. Many drugs have been …

Belimumab (Benlysta®) is a human immunoglobulin G1λ monoclonal antibody that inhibits
the binding of soluble B lymphocyte stimulator to B cells. It is the only biological agent …

Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect multiple
organ systems and whose hallmark is the production of autoantibodies. 1–3 A diagnosis of …

Systemic lupus erythematosus (SLE) is a complex autoimmune rheumatic disease with
multiple presentations, whose management presents many challenges. Many disease …

With the approval by the FDA in 2011 of a biologic agent (namely belimumab) for the
treatment of systemic lupus erythematosus (SLE), optimism abounds that additional biologic …

Systemic lupus erythematosus (SLE) is an autoimmune disorder that afflicts 500,000 people
in the United States. There has not been a new SLE drug approved in the United States …

Biologics in the treatment of systemic lupus erythematosus : Current Opinion in Rheumatology
Biologics in the treatment of systemic lupus erythematosus : Current Opinion in Rheumatology …